<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624723</url>
  </required_header>
  <id_info>
    <org_study_id>INCB054707-106</org_study_id>
    <nct_id>NCT05624723</nct_id>
    <nct_alias>NCT05694195</nct_alias>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis</brief_title>
  <official_title>A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707&#xD;
      in participants with varying levels of renal function or impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2023</start_date>
  <completion_date type="Anticipated">August 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter: Cmax of INCB054707</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Defined as maximum observed plasma concentration of INCB054707</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter: AUC0-t of INCB054707</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Area Under the concentration- time curve up to the last measurable concentration of INCB054707</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter: AUC0-∞ of INCB54707</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Defined as under the concentration-time curve up to the last measurable concentration of INCB054707</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAE'S)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter: tmax of INCB054707</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Defined as time to reach maximum plasma concentration of INCB054707; during dialysis for Group 5 Period 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter: t½ of INCB054707</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Defined as apparent terminal-phase disposition half-life of INCB054707; during dialysis for Group 5 Period 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter: CL/F of INCB054707</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Defined as oral dose clearance of INCB054707; during dialysis for Group 5 Period 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter: Vz/F of INCB054707</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Defined as apparent oral dose volume of distribution; during dialysis for Group 5 Period 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter: AUC3-7 of INCB054707</measure>
    <time_frame>Days 1-4</time_frame>
    <description>Defined as area under the concentration-time curve from 1 to 5 of INCB054707; during dialysis for Group 5 Period 1.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Renal Insufficiency</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1: Normal Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Kidney Failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5 participants with ESRD maintained on HD will receive a single dose of INCB054707 across 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB054707.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054707</intervention_name>
    <description>INCB054707 75 mg will be administered orally</description>
    <arm_group_label>Group 1: Normal Renal Function</arm_group_label>
    <arm_group_label>Group 2: Mild Renal Impairment</arm_group_label>
    <arm_group_label>Group 3: Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Group 4: Severe Renal Impairment</arm_group_label>
    <arm_group_label>Group 5: Kidney Failure</arm_group_label>
    <other_name>Povorcitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Classification at screening by renal function based on eGFR as calculated by the MDRD&#xD;
             formula and requirement for HD (Group 5).&#xD;
&#xD;
          -  Participants eligible for Group 5 with ESRD have received HD for at least 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Participants eligible for Group 1 should be in good health as determined by no&#xD;
             clinically significant deviations from normal for medical history, physical&#xD;
             examination, vital signs, 12-lead ECGs, or clinical laboratory determinations at&#xD;
             screening or Day -1.&#xD;
&#xD;
          -  Participants eligible for Groups 2 through 5 may have medical findings consistent with&#xD;
             their degree of renal dysfunction, as determined by medical history, physical&#xD;
             examination, vital signs, 12-lead ECGs, and clinical laboratory determinations at&#xD;
             screening and Day -1 (Groups 2 through 4) or Period 1 Day -1 (Group 5).&#xD;
&#xD;
          -  Body mass index within the range of 18.0 to 40.0 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of uncontrolled or unstable cardiovascular, respiratory, hepatic, GI,&#xD;
             endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of&#xD;
             screening or evidence of rapidly deteriorating renal function.&#xD;
&#xD;
          -  Current, functioning organ transplant or a cheduled organ transplant within 6 weeks&#xD;
             after check-in.&#xD;
&#xD;
          -  History of malignancy within 5 years of screening, with the exception of cured basal&#xD;
             cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or&#xD;
             Gleason 6 prostate cancer.&#xD;
&#xD;
          -  History of clinically significant GI disease or surgery (cholecystectomy and&#xD;
             appendectomy are allowed) that could impact the absorption of study drug.&#xD;
&#xD;
          -  Eligible for Group 1 and have a history of renal disease or renal injury as indicated&#xD;
             by an abnormal, clinically significant renal function profile at screening or Day -1.&#xD;
&#xD;
          -  Eligible for Groups 2 through 5 and have had a change in disease status within 30 days&#xD;
             of screening, as documented by the participant's medical history and deemed clinically&#xD;
             significant by the investigator.&#xD;
&#xD;
          -  History or current diagnosis of uncontrolled or significant cardiac disease indicating&#xD;
             significant risk of safety for participation in the study, including any of the&#xD;
             following:&#xD;
&#xD;
               1. Recent myocardial infarction (within 6 months of check-in)&#xD;
&#xD;
               2. New York Heart Association Class III or IV congestive heart failure&#xD;
&#xD;
               3. Unstable angina (within 6 months of check-in)&#xD;
&#xD;
               4. Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained&#xD;
                  ventricular tachycardia, second- or third-degree atrioventricular block without a&#xD;
                  pacemaker)&#xD;
&#xD;
               5. Uncontrolled hypertension&#xD;
&#xD;
          -  Any major surgery within 4 weeks of screening.&#xD;
&#xD;
          -  Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for&#xD;
             plasma only).&#xD;
&#xD;
          -  Blood transfusion within 4 weeks of Day -1 (for Groups 1 through 4) or Period 1 Day -1&#xD;
             (Group 5).&#xD;
&#xD;
          -  Chronic or current active infectious disease requiring systemic antibiotic,&#xD;
             antifungal, or antiviral treatment.&#xD;
&#xD;
          -  Positive test and symptomatic for HBV, HCV, or HIV. Participants whose results are&#xD;
             compatible with prior immunization for or immunity due to infection with HBV may be&#xD;
             included at the discretion of the investigator.&#xD;
&#xD;
          -  Eligible for Group 1 and have a history of using tobacco- or nicotine-containing&#xD;
             products within 6 months of screening.&#xD;
&#xD;
          -  Eligible for Groups 2 through 5 and smoke &gt; 10 cigarettes per day or equivalent use of&#xD;
             other tobacco- or nicotine-containing products and are unwilling to refrain from&#xD;
             tobacco or nicotine use on dosing days and abide by CRU restrictions.&#xD;
&#xD;
          -  History of alcohol dependency within 3 months of screening.&#xD;
&#xD;
          -  Positive breath test for ethanol or positive urine or saliva screen for drugs of abuse&#xD;
             (confirmed by repeat test) at screening or check-in that are not otherwise explained&#xD;
             by permitted concomitant medications.&#xD;
&#xD;
          -  Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of&#xD;
             study drug administration with another investigational medication or current&#xD;
             enrollment in another investigational drug study.&#xD;
&#xD;
          -  Current treatment or treatment within 15 days or 5 half-lives (whichever is longer)&#xD;
             before the first dose of study drug with moderate and potent inducers or inhibitors of&#xD;
             CYP3A4 (refer to the Drug Interaction Database Program [University of Washington&#xD;
             School of Pharmacy 2002] for prohibited drugs).&#xD;
&#xD;
          -  Consumption of Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus&#xD;
             fruits, grapefruit hybrids, or fruit juices within 72 hours before the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Eligible for Group 1 and have used prescription drugs within 14 days of study drug&#xD;
             administration or nonprescription medications/products (including vitamins, minerals,&#xD;
             and hytotherapeutic/herbal/plant-derived preparations) within 7 days of study drug&#xD;
             administration. However, occasional use of acetaminophen and ibuprofen is permitted&#xD;
             (see Section 6.6.1).&#xD;
&#xD;
          -  Eligible for Groups 2 through 5 and have used prescription drugs within 14 days of&#xD;
             study drug administration, with the exception of established therapy for renal disease&#xD;
             and the treatment of associated disorders that have been stable for at least 7 days&#xD;
             prior to study drug administration, as approved by the investigator and in&#xD;
             consultation with the sponsor's medical monitor.&#xD;
&#xD;
          -  Current or recent history (within 30 days before screening) of a clinically&#xD;
             significant bacterial, fungal, parasitic, or mycobacterial infection, currently&#xD;
             receiving systemic antibiotics, or having a current clinically significant viral&#xD;
             infection at screening or check-in.&#xD;
&#xD;
          -  History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed&#xD;
             clinically relevant by the investigator.&#xD;
&#xD;
          -  Inability to undergo venipuncture or tolerate venous access.&#xD;
&#xD;
          -  Eligible for Group 5 and not expected to continue HD treatment for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Use of hormonal contraception&#xD;
&#xD;
          -  QTcF &gt; 450 milliseconds for Groups 1 through 3 and QTcF &gt; 470 milliseconds for Group&#xD;
             4.&#xD;
&#xD;
          -  Eligible for Group 1 and have abnormal LFT values, defined as aspartate&#xD;
             aminotransferase, alanine aminotransferase, and serum (total and direct) bilirubin, as&#xD;
             well as amylase and lipase above the upper limit of the normal range at screening.&#xD;
&#xD;
          -  Eligible for Groups 2 through 4 and have values outside the normal ranges for LFTs;&#xD;
             however, values may be acceptable if they are consistent with the participant's renal&#xD;
             condition (if stable for 1 month prior to screening) and if the investigator (or&#xD;
             designee) and the sponsor feel that the results are not clinically significant (based&#xD;
             on age and renal impairment status).&#xD;
&#xD;
          -  Receipt of live (including attenuated) vaccines within 3 months of check-in or&#xD;
             anticipation of need for such a vaccine during the study (Note: Nonlive or inactivated&#xD;
             vaccines are allowed up to 2 weeks prior to the first dose of study drug).&#xD;
&#xD;
          -  Known hypersensitivity or severe reaction to INCB054707 or excipients of INCB054707&#xD;
             (refer to the IB).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apex Gmbh</name>
      <address>
        <city>Munich</city>
        <zip>D-81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>February 28, 2023</last_update_submitted>
  <last_update_submitted_qc>February 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal impairment</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>Kidney failure</keyword>
  <keyword>end-stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

